PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-3.99%
Negative revenue growth while 3088.T stands at 4.69%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-3.25%
Negative gross profit growth while 3088.T is at 8.20%. Joel Greenblatt would examine cost competitiveness or demand decline.
-19.17%
Negative EBIT growth while 3088.T is at 25.71%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-27.13%
Negative operating income growth while 3088.T is at 29.14%. Joel Greenblatt would press for urgent turnaround measures.
-25.66%
Negative net income growth while 3088.T stands at 33.34%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-25.65%
Negative EPS growth while 3088.T is at 300.91%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-25.65%
Negative diluted EPS growth while 3088.T is at 300.80%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-0.00%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-0.00%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
No Data
No Data available this quarter, please select a different quarter.
5.51%
OCF growth of 5.51% while 3088.T is zero. Bruce Berkowitz would see if small gains can expand into a larger competitive lead.
5.51%
FCF growth of 5.51% while 3088.T is zero. Bruce Berkowitz would see if modest improvements in free cash can accelerate further.
27.44%
10Y revenue/share CAGR under 50% of 3088.T's 104.37%. Michael Burry would suspect a lasting competitive disadvantage.
49.80%
5Y revenue/share CAGR at 50-75% of 3088.T's 70.85%. Martin Whitman would worry about a lagging mid-term growth trajectory.
23.09%
3Y revenue/share CAGR under 50% of 3088.T's 53.90%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
13.42%
Below 50% of 3088.T's 281.73%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
53.29%
Below 50% of 3088.T's 114.61%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
29.45%
Below 50% of 3088.T's 64.37%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
143.96%
Below 50% of 3088.T's 302.20%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
100.32%
5Y equity/share CAGR at 50-75% of 3088.T's 144.65%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
49.44%
Below 50% of 3088.T's 116.16%. Michael Burry suspects a serious short-term disadvantage in building book value.
112.50%
Below 50% of 3088.T's 250.00%. Michael Burry might see weaker long-term distribution growth, raising questions about the firm's capital allocation.
88.89%
5Y dividend/share CAGR above 1.5x 3088.T's 40.00%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
70.00%
3Y dividend/share CAGR of 70.00% while 3088.T is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
29.48%
AR growth well above 3088.T's 0.54%. Michael Burry fears inflated revenue or higher default risk in the near future.
10.13%
Inventory growth well above 3088.T's 0.24%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
1.50%
Asset growth well under 50% of 3088.T's 3.05%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
2.47%
50-75% of 3088.T's 3.65%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
-8.57%
We’re deleveraging while 3088.T stands at 0.48%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
3.12%
We expand SG&A while 3088.T cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.